MARKETING RESEARCH OF THE MEDICINE MARKET FOR THE TREATMENT OF BREAST CANCER IN UKRAINE

Анотація

the article presents the results of the study of the marketing market of medicines for the treatment of
 breast cancer in Ukraine during 2019-2020. Medicine treatment schemes based on a clinical protocol were ana-lyzed. On December 1, 2019, 184 drugs were registered for the treatment of breast cancer in Ukraine, and on De-cember 1, 2020 - 194. In 2020, the largest share among of the studied drugs belongs to the group of antineoplastic
 and immunomodulatory drugs - 82.0 %, and the group of drugs that affect the musculoskeletal system - 18.0 %. OnDecember 1, 2020, drugs were represented by 43 manufacturers, of which 18.6 % were Ukrainian and 81.4 % wereforeign. Among Ukrainian companies, the primacy belongs to Pharmex Group LLC (4.1 %), Teva Ukraine LLC (3.1%) and Farmak JSC (2.6 %). The largest share of foreign suppliers occupies Great Britain - 26.3 %, Switzerlandand India by 11.9 %. At that time, in 5 pharmacotherapeutic groups (L01AA01, L01BA01, L01CA04, L01XC07,
 M05BA03) is not represented by any drug Ukrainian manufacturer. Analysis of the assortment of drugs for the treat-ment of breast cancer by dosage form in 2020 showed that the main share (35.6 %) is represented by concentrate for
 solution for infusion, 21.6 % - tablets and 20.6 % - lyophilisate for solution for infusion. Other dosage forms forma total of 22.2 % of the total assortment of drugs, studied in the Ukrainian market.

Класифікація

Ідентифікатори

Схожі роботи